Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 28 tags : Biotech-bay save search
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
ATRA | $0.6917 -3.25% -3.35% 770K
|
Health Technology
|
| O: 0.2%
H: 4.26%
C: 4.2%
financial results results iot
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
SGMO | $0.4851 -5.99% -6.33% 1.6M
|
Health Technology
|
| O: 0.25%
H: 4.31%
C: 4.13%
conference therapeutics
Gilead Sciences Announces Third Quarter 2021 Financial Results
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 4.9M
|
Health Technology
|
| O: -0.1%
H: 1.44%
C: 0.96%
financial results results
Agilent to Webcast Fourth-Quarter Fiscal Year 2021 Financial Results Presentation
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
A | $132.44 -1.57% 0.0% 1.6M
|
Health Technology
|
| O: 0.46%
H: 1.16%
C: -0.14%
presentation financial results results
Bio-Rad Reports Third-Quarter 2021 Financial Results
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
BIO | News | $281.02 -3.38% 0.0% 370K
|
Health Technology
|
| O: 0.67%
H: 3.26%
C: 2.48%
financial results results
Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 4.9M
|
Health Technology
|
| O: -0.1%
H: 1.44%
C: 0.96%
collaboration cancer breast cancer trial keytruda
Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Triple-Negative Breast Cancer (TNBC)
Published: 2021-10-28 (Crawled : 22:00) - biospace.com/
A | $132.44 -1.57% 0.0% 1.6M
|
Health Technology
|
| O: 0.46%
H: 1.16%
C: -0.14%
europe cancer breast cancer diagnostic
CytomX Therapeutics to Announce Third Quarter 2021 Financial Results on November 4, 2021
Published: 2021-10-28 (Crawled : 13:15) - biospace.com/
CTMX | $1.73 -1.7% -1.44% 200K
|
Health Technology
|
| O: 1.09%
H: 7.85%
C: 7.22%
financial results results
Gainers vs Losers
| 60% | 40% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.